Latvia vs Papua New Guinea: Access to anti-retroviral drugs, male
Latvia
51.0%
in 2024
Papua New Guinea
50.0%
in 2024
Latvia rank
116th
Papua New Guinea rank
117th
Access to anti-retroviral drugs, male over time
- Latvia
- Papua New Guinea
How they compare
Latvia currently reports 51.0% against 50.0% in Papua New Guinea, a difference of 1.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Latvia ahead.
Latvia ranks 116th and Papua New Guinea ranks 117th of 141 countries.
Across the 3 decades both report, Latvia averaged higher in 1 and Papua New Guinea in 2.
Head to head by decade
| Decade | Latvia | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.3% | 4.0% | 0.7% | Papua New Guinea |
| 2010s | 22.3% | 28.3% | 6.0% | Papua New Guinea |
| 2020s | 49.0% | 45.0% | 4.0% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Latvia or Papua New Guinea?
- Latvia, at 51.0% against 50.0% in Papua New Guinea as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Latvia and Papua New Guinea?
- 1.0%, with Latvia ahead.
- How many years of comparable data are there for Latvia and Papua New Guinea?
- 25 years are reported by both, from 2000 to 2024.
- How do Latvia and Papua New Guinea rank globally for access to anti-retroviral drugs, male?
- Latvia ranks 116th and Papua New Guinea ranks 117th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.